Menu
NASP

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Hemophilia in Specialty Pharmacy

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.


 

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
 

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.

Hemophilia is a complex disease state that requires a working knowledge of the many factors that influence treatment. This activity will review hemophilia as it pertains to specialty pharmacy. Treatment choices for hemophilia A and B are discussed. Inhibitor development will be explained including diagnosis and treatment options as well as the impact to therapy. Specific considerations in dispensing factor are outlined and new and pipeline therapies are reviewed.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

  • Express a general understanding of the etiology of hemophilia.
  • Recognize appropriate treatment options based on specific hemophilia diagnosis.
  • Describe how the development of an inhibitor impacts treatment considerations.
  • Discuss variables in dispensing factor prescriptions.
  • Recognize Hemlibra’s place in therapy.
  • Review new and pipeline treatment options.

Faculty

Erin Mellerski, PharmD, CSP
Cottrill’s Pharmacy, Inc.
Orchard Park, NY

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Mellerski has no relevant commercial or financial relationships to disclose.

CE Accreditation

Release Date: 11-1-2019
Expiration Date: 11-19-2022

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-511-H01-P has been assigned to this knowledge-based home-study CE activity. This activity is approved for 0.5 contact hour (0.05 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

No external support has been received for this activity.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.